Momex

Quick links to important sections

Momex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Momex

Property Description
Active ingredient Mometasone furoate
Form Cream, Ointment, or Lotion
Pharmacological class Topical Corticosteroid (Glucocorticoid)
Common use Relieving inflammation, redness, and itching of the skin
Origin Synthetic

What Type of Medicine is Momex?

Momex is classified as a potent topical corticosteroid, placing it within the broader pharmacological group of glucocorticoids, and is formulated for direct application to the skin. The medication's identity is defined by its active component, mometasone furoate, which is a synthetic steroid derivative that works by reducing the production of inflammatory chemicals in the skin. Mometasone furoate is widely recognized across clinical guidelines as a high-potency agent (Group III). This classification clarifies that the medication is designed for conditions requiring a robust intervention to suppress inflammation effectively, and it is typically available only as a prescription-only medicine.

Composition and Available Dermatologic Forms

The core composition of Momex features the single active ingredient, mometasone furoate, suspended in a specialized vehicle suitable for dermatologic administration. As a topical preparation, the medicine is available in various forms, including cream, ointment, and lotion or solution, offering versatility for different skin types and lesion characteristics. These formulations are strategically engineered to deliver the active component effectively; for instance, the heavier ointment base is typically used for dry, thickened skin patches. Pharmacological studies confirm that mometasone furoate maintains excellent local activity across these various topical vehicles.

The General Purpose of Mometasone Topical

The principal purpose of Momex is to provide relief from the localized signs and symptoms of inflammatory skin conditions that are responsive to corticosteroid treatment, such as dermatitis. The potent action of the glucocorticoid enables it to rapidly decrease localized swelling and redness by interfering with the body's inflammatory cascade. Furthermore, its pronounced anti-pruritic action is crucial, providing significant relief from the persistent, uncomfortable sensation of itchiness that characterizes dermatoses, thereby helping to stabilize the skin and alleviate patient discomfort.

Regulatory References

  1. Mometasone Furoate Cream label

What side effects are possible with Momex?

Possible Side Effects and Safety Information

Momex, containing the potent corticosteroid mometasone furoate, is associated with a risk profile documented across official regulatory labeling. Adverse reactions are primarily grouped into local skin effects and potential systemic consequences resulting from absorption.


Documented Adverse Reactions

The most frequently observed adverse reactions at the application site, as cited in clinical trials for the cream formulation, include burning, pruritus (itching), and skin atrophy (thinning). Other effects documented in regulatory labeling across various frequency categories (such as uncommon or not known) include folliculitis, hypertrichosis (increased hair growth), acneiform eruptions, striae (stretch marks), and hypopigmentation.


Systemic Safety and Special Populations

As a potent topical glucocorticoid, systemic absorption can lead to serious adverse reactions, notably the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome. Ophthalmic risks such as Glaucoma and Cataracts are also documented safety concerns, particularly with prolonged use or application near the eye.

Safety notes specify that pediatric patients may exhibit greater susceptibility to systemic toxicity due to body mass ratio, and use for longer than three weeks is not established in children 2 years or older. Furthermore, the label defines safety-related restrictions, noting that use is not recommended in conditions such as facial rosacea, acne vulgaris, or in the presence of various local skin infections.

Overdose and Emergency Response

Overdose and When to Seek Help

Overuse of Momex (mometasone furoate) nasal spray, particularly for prolonged periods at doses higher than recommended, is the primary risk factor for overdose effects. As a corticosteroid, the chief concern from excessive use is the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

This condition can lead to clinically significant adrenal suppression, which impacts the body's natural ability to produce corticosteroid hormones, especially in response to stress. Symptoms of adrenal insufficiency, such as severe tiredness, weakness, dizziness, or loss of appetite, should be reported to a healthcare provider promptly.

Overdose Concern Clinical Manifestation
HPA Axis Suppression Adrenal insufficiency (fatigue, muscle weakness, mood changes)
High Dose Exposure Hypercorticism (moon face, weight gain in the upper back or abdomen)

If there is any evidence of prolonged use at higher than recommended doses, a healthcare provider may need to monitor adrenal function. Patients who are switching from long-term systemic corticosteroids to an intranasal product require particularly close monitoring. In times of physical stress, such as major surgery or illness, additional systemic corticosteroid treatment may be necessary to manage the suppressed HPA axis. Do not stop treatment abruptly or change the dose without medical guidance. In the event of a suspected overdose, contact emergency services or a poison control center immediately.

Therapeutic Uses of Momex

What Momex Treats: Main Uses and Benefits

Momex is a specialized topical medication used for the symptomatic management of inflammatory skin conditions that involve inflammatory or irritative states, offering focused relief when symptoms become difficult to tolerate. This medication is commonly used to help with conditions characterized by periods of heightened symptoms such as atopic dermatitis (eczema), various forms of psoriasis, and seborrheic dermatitis.

The medication provides therapeutic support by helping address the most distressing symptomatic cluster: intense itching (pruritus), pronounced redness (erythema), and localized swelling. Using this agent contributes to easing the overall symptom load, supporting the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.

This application provides necessary supportive relief to address the physical discomfort during acute or episodic phases, may help patients cope more steadily with symptom fluctuations, and supports functional stability.

Quick Fact: Symptomatic support for Itching and Inflammation

Eligibility and Restrictions for Use

Eligibility Scope

The official eligibility profile for Momex (mometasone furoate topical) is strictly defined by regulatory documents, distinguishing between approved, restricted, and contraindicated populations.

Category Regulatory Status
Populations Allowed Adults and adolescents (ge 12 years); Children 2 years and older (with strict limitations)
Populations Contraindicated Patients with known hypersensitivity to any component; Those with untreated skin infections (viral, bacterial, fungal); Patients with facial rosacea, acne vulgaris, or perioral dermatitis; Use in the eyes/eyelids; Use in the diaper area of infants
Populations Not Recommended Children below 2 years of age; Use for periods longer than 3 weeks in children ge 2 years; Use with occlusive dressings

Age-Related and Conditional Use

Age-Related Eligibility: Safety and efficacy have not been established in children under 2 years of age, leading to the not recommended status. In children 2 years and older, use is conditional and limited due to the increased risk of systemic absorption. Older adults may also be more susceptible to systemic effects and are advised to use the medication with caution.

Pregnancy and Lactation: Use during pregnancy is restricted (e.g., US FDA Category C) and is generally permitted only if the benefit justifies the potential risk. For breastfeeding, a decision must be made to discontinue the drug or breastfeeding, and application to the breast area must be avoided.


Connection to the overall eligibility profile

Regulatory authorities define who can and cannot use the medicine by establishing clear prohibitions based on specific skin conditions or allergies, and conditional use categories for vulnerable populations (age, pregnancy, hepatic impairment), reflecting the potent nature of the topical corticosteroid.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Momex (Mometasone furoate topical) is defined by the potential for systemic absorption and subsequent metabolic and pharmacodynamic interactions documented in regulatory labels.

Systemic Exposure and Metabolic Interactions

Mometasone furoate is identified as a substrate of the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors, such as Ritonavir or Itraconazole, may reduce the clearance of absorbed mometasone and result in increased systemic exposure. This change in concentration officially heightens the risk of systemic corticosteroid effects. Consumption of Grapefruit products is also documented as a metabolic constraint that may increase the plasma concentration of mometasone furoate.

Pharmacodynamic and Formal Restrictions

Concurrent use with other corticosteroid-containing products (including oral, inhaled, or other topical forms) is associated with an official risk of additive systemic effects, increasing the total glucocorticoid load. The combination with Mifepristone is a formal contraindication in patients receiving long-term corticosteroid treatment due to the critical interaction risk of precipitating acute adrenal insufficiency. Interaction risks are also officially heightened in pediatric patients and when the product is applied to large surface areas or damaged skin, due to increased systemic absorption.

Mechanism of Action

How Momex Works: Mechanism of Action

u1f9ec Intracellular Glucocorticoid Receptor Activation

Momex (Mometasone furoate) acts as a high-affinity agonist for the Glucocorticoid Receptor ( GR) within skin cells, initiating a cascade of gene regulation. This action involves the GR complex translocating to the nucleus, where it suppresses pro-inflammatory transcription factors ( NF-κB and AP-1) while boosting anti-inflammatory proteins ( Lipocortin-1), resulting in modulation of the local immune response.

——-

u1f4a5 Blockade of Pro-Inflammatory Mediator Cascades

The drug's genomic effect halts the synthesis of mediators by increasing Lipocortin-1, which subsequently inhibits the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the formation of Arachidonic Acid—the precursor to lipid inflammatory substances like prostaglandins and leukotrienes—is prevented, significantly reducing activity within the pathway that fuels local physiological responses.

——-

u1f9e7 Modulation of Tissue Dynamics and Microcirculation

This mechanism translates molecular changes into physiological consequences by causing vasoconstriction and dramatically reducing capillary permeability. By limiting blood flow and decreasing the migration of immune cells into the tissue, the drug reduces the local fluid accumulation and cellular activity, contributing to changes in microcirculatory dynamics and cellular infiltration, and further inhibiting the activity of overactive pathways.

Dosage and Administration Information

Momex (mometasone furoate) is for topical administration onto the skin. The medicine is available as a 0.1% cream, ointment, or lotion, with the specific formulation choice often guided by the skin characteristics of the lesion.

The standard administration schedule for all official forms is an application of a thin film once daily to the affected skin area. This regimen is for use in both adults and pediatric patients aged 2 years and older; use in children younger than two years is not recommended. If a once-daily application is missed, it should be applied as soon as it is remembered unless it is almost time for the next scheduled application, in which case the missed dose should be skipped.

The overall duration of use is intended to be short-term. Treatment must be discontinued promptly once the skin condition is brought under control, thereby minimizing total exposure. If no clinical improvement is observed after two weeks of consistent once-daily use, the diagnosis and treatment plan should be formally re-evaluated.

A key procedural constraint is the avoidance of occlusive dressings (including bandages, tight clothing, or diapers) over the application site, as this can alter absorption. Furthermore, application to sensitive areas, such as the face, groin, or axillae, should be minimized and is typically restricted to a duration of five days or less. The product is for external use only, and contact with the eyes must be avoided.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Momex

Evidence for use in Atopic Dermatitis (Eczema)

The evidence base for Momex was evaluated in studies of Atopic Dermatitis (eczema), a condition characterized by fluctuating or episodic manifestations, and is primarily built upon short-term Randomized Controlled Trials (RCTs). Researchers conducted these studies to explore the changes in symptoms over defined time intervals, often comparing Momex to an inactive placebo vehicle. The studies included both adult patients and children age two years and older. Research examined outcomes related to physical discomfort and inflammatory states, such as measuring the change in objective signs like redness (erythema) and swelling using standardized scoring systems.

Findings describe patterns observed in the studies where signs of inflammation were measured across the short-term duration, typically lasting two to four weeks. Studies also monitored patient-reported outcomes describing perceived discomfort, specifically focusing on the intensity of itching (pruritus).

Evidence for use in Psoriasis

Momex was evaluated in clinical trials and Phase III studies focusing on the symptomatic management of Plaque Psoriasis, a condition marked by functional limitations and characteristic inflammatory lesions. Research examined temporary physiological imbalance by monitoring signs of inflammation. Studies explored changes in physical outcomes such as the degree of plaque scaling, thickness, and redness using clinical assessment tools. The core population studied was adult patients with mild to moderate disease severity. Trials also applied in studies examining patient-reported experiences related to itching.

Long-term effects are not fully established, as most core efficacy research focuses on the short-term clearance of lesions. Furthermore, comparative evidence is lacking that fully evaluates Momex against the entire range of alternative high-potency treatments.

What is Still Uncertain About the Research

The evidence base suggests that the available research provides context but not individual predictions, and highlights what is known and what is still uncertain. The evidence quality for acute symptom management in the core indications is often described as high; however, several research limitation frames apply:

  • Long-term effects are not fully established: The current body of evidence is weighted towards short-term, acute symptom evaluation, and there is limited information for the long-term outcomes when Momex is used over many years.
  • Data for certain groups remain insufficient: The evidence quality varies across studies, and data for specific subgroups, such as the use of the drug during pregnancy or in very young children (under 2 years of age), remains limited.

Key Studies & References

  1. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis
  2. Comparative Efficacy of Tacrolimus and Mometasone Furoate in Topical Treatment for Atopic Dermatitis: A Randomized Controlled Trial
  3. MOMETASONE FUROATE cream - DailyMed (NIH/FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Momex (FAQ)

Q: How long does it usually take to notice any effect from Momex?

A: Official information indicates that treatment should be reassessed if no clinical improvement is observed after two weeks of consistent daily application. This timeframe reflects the period of use over which effectiveness is assessed in regulatory documents.


Q: Is Momex okay to use during pregnancy or while breastfeeding?

A: Regulatory documents state that there is inadequate evidence of safety in human pregnancy. Use of the medication during pregnancy or lactation is generally permitted only if the potential benefit justifies the potential risk, as described in official documents. For breastfeeding, official guidance states that a decision must be made to discontinue the drug or discontinue breastfeeding.


Q: What are the reported effects of stopping Momex suddenly?

A: Regulatory information documents the potential for a withdrawal reaction upon sudden discontinuation of long-term, potent topical treatment. This reaction may involve skin redness that extends beyond the treated area, a burning or stinging sensation, itching, or skin peeling. Furthermore, systemic effects like HPA axis suppression may also occur after treatment withdrawal.


Q: Does Momex cause weight gain or weight loss?

A: Significant weight gain (especially in the upper back or belly) or weight loss can be a sign of a potential systemic side effect, specifically the manifestations of Cushing's syndrome or adrenal gland insufficiency. These rare effects can occur due to the systemic absorption of the topical corticosteroid.


Q: Are there studies comparing Momex to a placebo?

A: Yes, official clinical studies and regulatory evidence evaluating Momex for conditions like atopic dermatitis and psoriasis have involved comparisons of the medication against an inactive placebo vehicle. This is a standard method used by researchers to determine a medicine’s effectiveness.


Q: Does Momex interact with herbal remedies?

A: Official interaction information addresses co-administration with strong CYP3A4 inhibitors. Since this is an enzyme the body uses to process the drug, co-use with an inhibitor, which may include certain herbal products, could potentially increase the amount of the drug absorbed into the body.


Q: Can Momex be used long-term?

A: Treatment with Momex is defined for short-term use. Regulatory documents specify limitations for long-term administration, noting that use is typically limited to a maximum of three weeks in children, and use for long periods is generally not recommended.


Q: Can Momex affect blood pressure?

A: Changes in blood pressure may occur as a potential manifestation of systemic side effects, such as Cushing's syndrome. This is due to the systemic absorption of the topical corticosteroid, which can affect the body's hormonal balance and is a reason for the drug’s limited use duration.


Q: Is Momex known to interact with alcohol?

A: Official documents for topical corticosteroids generally note a requirement for discussion or caution regarding co-administration with substances like alcohol or tobacco, due to the potential for systemic absorption.


Q: Is Momex a narcotic or controlled substance?

A: No. Momex (mometasone furoate topical) is officially classified by the U.S. Drug Enforcement Administration (DEA) as a non-controlled substance. It is a prescription-only medicine but is not subject to the stricter regulations of controlled substances.


Q: What happens if Momex is used past its expiration date?

A: Regulatory guidance indicates that the product's safety, stability, and full potency can no longer be guaranteed by the manufacturer after the labeled expiration date. Therefore, any use past that time is not supported by the manufacturer's official guarantees.


Q: Is there a risk of dependence or addiction associated with Momex?

A: While it is not considered an addictive substance, prolonged or inappropriate use of potent topical corticosteroids can lead to physical dependence. This risk is reflected in regulatory warnings about HPA axis suppression and the potential for a severe withdrawal reaction when the medicine is stopped.


Q: What happens in the body when Momex starts working?

A: Momex works inside the skin cells by activating the Glucocorticoid Receptor to reduce the production of inflammatory chemicals. This process decreases local fluid accumulation and limits the activity of overactive pathways. The result is a reduction in the visible signs of inflammation, such as swelling, redness, and itching.


Q: Are there specific medical tests required before starting Momex?

A: Official documents do not mandate a specific baseline test before starting treatment. However, due to the risk of systemic absorption, patients may be periodically evaluated during treatment using specific medical tests to monitor systemic effects, such as for HPA axis suppression.

How should Momex be stored and disposed of?

Official Storage and Disposal Requirements

Momex (mometasone furoate topical) must be stored according to regulatory labeling to maintain stability and prevent misuse. Storage conditions are defined by both temperature and environmental protection.

Requirement Type Official Condition
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Do not freeze and store away from excess heat and moisture.
Container Keep in the original container with the cap/tube tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal

Official disposal instructions prohibit discarding the unused product via wastewater or general household trash. Expired or unused medicine should be disposed of by following local regulations for pharmaceutical waste or utilizing a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Momex found in:

A-Z Index: